Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued a
- Ratio
- one-for-two
- Reverse split
- yes
- Effective
- November 20, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The split reduces share count, may improve per‑share price metrics, and sets the stage for the post‑merger ticker AVZO.
Market read
Primary corporate action for a small‑cap biotech; relevant for traders tracking split‑related volatility and merger outcomes.
What to watch
Potential Nasdaq listing requirements and cash‑in‑lieu for fractional shares could affect shareholder sentiment.
Background
Rallybio (Nasdaq: RLYB) filed an 8‑K detailing a reverse stock split tied to its merger with Avenzo Therapeutics.
Ticker impact
Rallybio announced a one‑for‑two reverse stock split and its pending merger with Avenzo, with the split effective Nov 20 2026.
likely pressure as the market adjusts to the split and merger timeline
Reverse splits often trigger trading activity; the pending merger adds uncertainty, leading to modest downside risk until completion.
Market effects
Biotech sector may see slight re‑rating as Rallybio consolidates with Avenzo, potentially affecting peer valuations.
Limited to US small‑cap biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the merger proceeds smoothly, the split could be a catalyst for upside as the combined entity gains scale.
Key entities
- CompanyRallybio Corp
US‑listed biotech announcing reverse split and merger.
- CompanyAvenzo Therapeutics
Clinical‑stage biotech merger partner.
